Indianapolis-based Corteva, Inc. (CTVA) supplies products to the agricultural input industry that protect against weeds, insects, pests, and diseases as well as enhance crop health. It operates through the Seed and Crop Protection segments. With a market cap of $49.2 billion, Corteva’s operations span the Americas, the Indo-Pacific, and EMEA.
The agricultural inputs giant is expected to release its Q2 results after the market closes on Wednesday, Aug. 6. Ahead of the event, analysts predict CTVA to deliver a profit of $1.89 per share, up a modest 3.3% from $1.83 per share reported in the year-ago quarter. While the company has missed the Street’s bottom-line projections twice over the past four quarters, it has surpassed the estimates on two other occasions.
For the full fiscal 2025, CTVA is expected to report an EPS of $3.01, up 17.1% from $2.57 reported in fiscal 2024. In fiscal 2026, its earnings are expected to further surge 15% year-over-year to $3.46 per share.
CTVA stock prices have soared 34.7% over the past 52 weeks, notably outperforming the S&P 500 Index’s ($SPX) 10.5% gains and the Materials Select Sector SPDR Fund’s (XLB) 2.9% dip during the same time frame.
Corteva’s stock prices surged over 7% in the trading session after the release of its mixed Q1 results on May 7. While the company faced currency headwinds and a drop in organic revenues in Latin America and Indo-Pacific, its organic revenues increased by 6% in North America. The company’s overall topline for the quarter dropped 1.7% year-over-year to $4.4 billion, missing the consensus estimates by 3.1%. However, its non-GAAP EPS grew by an impressive 27% year-over-year to $1.13, exceeding the Street's expectations by 29.9%, boosting investor confidence.
The stock maintains a consensus “Strong Buy” rating overall. Of the 21 analysts covering the CTVA stock, opinions include 14 “Strong Buys,” two “Moderate Buys,” and five “Holds.” Its mean price target of $77.65 represents a modest 6.4% upside potential from current price levels.
